NEWARK, Calif., May 7, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that Larry Mattheakis, Ph.D., SVP Discovery Biology and Translational Research, will present results of preclinical studies of PN-943, an oral, gut-restricted alpha-4-beta-7 integrin antagonist peptide in clinical development for the treatment of inflammatory bowel disease, at the annual Digestive Disease Week (DDW) conference. Details of the oral presentation, selected for a Distinguished Abstract Plenary, are as follows:
Title: The oral alpha-4-beta-7 integrin specific antagonist PN-10943 is more effective than PTG-100 in multiple preclinical studies (Abstract #3155395)
Session: Immunology, Microbiology & Inflammatory Bowel Diseases (IMIBD) Section Distinguished Abstract Plenary
Session Date and Time: Sunday, May 19, 4:00 p.m. - 5:30 p.m. PDT
Presentation Date and Time: Sunday, May 19, 5:10 p.m. to 5:24 p.m. PDT
Location: 20BCD, San Diego Convention Center
DDW, the world's largest gathering of physicians, researchers and industry in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery, is being held at the San Diego Convention Center May 18-21, 2019. Additional information is available at https://ddw.org.
About PN-943
PN-943 is an oral, gut-restricted alpha-4-beta-7 integrin antagonist peptide in development for the treatment of inflammatory bowel disease. PN-943 is designed to offer the convenience of oral administration and the potential for improved safety and tolerability compared to therapeutics administered by injection that target the alpha-4-beta-7 integrin pathway. Protagonist Therapeutics is evaluating PN-943 in a randomized, double-blind, placebo-controlled, dose escalation (100, 300, 1000 and 1400 mg) Phase 1 study in normal healthy volunteers.
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to transform existing treatment paradigms for patients with significant unmet medical needs. PTG-300 is an injectable hepcidin mimetic for the potential treatment of anemia and iron overload related rare blood diseases with an initial focus on beta-thalassemia. PTG-200 is an oral interleukin-23 receptor antagonist in development for the treatment of inflammatory bowel disease. The company has entered into a worldwide license and collaboration agreement with Janssen Biotech for the clinical development of PTG-200. PN-943 is an oral, gut-restricted alpha-4-beta-7 integrin antagonist peptide in development for the treatment of inflammatory bowel disease.
Protagonist is headquartered in Newark, California, with pre-clinical and clinical staff in California and discovery operations in both California and Brisbane, Queensland, Australia. For further information, please visit http://www.protagonist-inc.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, the potential for our clinical programs, the initiation and availability of results of our clinical trials and the sufficiency of our financial resources. In some cases, you can identify these statements by forward-looking words such as "anticipate," "believe," "may," "will," "expect," or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreement with Janssen, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. We discuss many of these risks in greater detail under the heading "Risk Factors" contained in our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the Securities and Exchange Commission. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.
SOURCE Protagonist Therapeutics, Inc.
